R-HCVAD regimen
|
WikiDoc Resources for R-HCVAD regimen |
|
Articles |
|---|
|
Most recent articles on R-HCVAD regimen Most cited articles on R-HCVAD regimen |
|
Media |
|
Powerpoint slides on R-HCVAD regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on R-HCVAD regimen at Clinical Trials.gov Trial results on R-HCVAD regimen Clinical Trials on R-HCVAD regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on R-HCVAD regimen NICE Guidance on R-HCVAD regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on R-HCVAD regimen Discussion groups on R-HCVAD regimen Patient Handouts on R-HCVAD regimen Directions to Hospitals Treating R-HCVAD regimen Risk calculators and risk factors for R-HCVAD regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for R-HCVAD regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: Rituximab-Hyper-Cyclophosphamide-Vincristine-Adriamycin-Dexamethasone regimen
Overview
R-HCVAD regimen refers to a regimen consisting of rituximab, cyclophosphamide, vincristine, doxorubicin (Adriamycin), and dexamethasone used to treat some forms of mantle cell lymphoma.[1]
Regimen
RRituximab
CCyclophosphamide
VVincristine (Oncovin)
ADoxorubicin (Adriamycin)
DDexamethasone
Indications
References
- ↑ 1.0 1.1 Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B; et al. (2005). "High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine". J Clin Oncol. 23 (28): 7013–23. doi:10.1200/JCO.2005.01.1825. PMID 16145068.